



# Evidera Presents at ISPOR Europe 2019

2-6 November 2019 – Copenhagen, Denmark

## SHORT COURSES

**Sat., Nov. 2, 08:00 – 12:00**  
**MORNING SESSION**

Introduction to the Design & Analysis of Observational Studies of Treatment Effects Using Retrospective Data Sources

Justo N, Martin B

**Sun., Nov. 3, 08:00 – 12:00**  
**MORNING SESSION**

Using Multi-Criteria Decision Analysis in Healthcare Decision Making- Approaches & Applications

Devlin N, IJzerman M, Marsh K

**Sun., Nov. 3, 13:00 – 17:00**  
**AFTERNOON SESSION**

Creating Natural, Flexible Models with DICE Simulation

Caro JJ, Moller J

## WORKSHOPS

**Mon., Nov. 4, 17:00 – 18:00**  
**BREAKOUT SESSION 4**

**W7: ADVANCED WORKSHOP:** Using Patient Preference Data to Support Reimbursement and Pricing Decisions: Current Practice, Opportunities, and Challenges

Mühlbacher AC, Marsh K, Ghabri S, Lundin D

**Tue., Nov. 5, 14:15 – 15:15**  
**BREAKOUT SESSION 6**

**W11: ADVANCED WORKSHOP:** Looking Beyond Statistical Adjustment to Untangle the Effects of Subsequent Treatments Selected by Investigators in Oncology Trials

Ishak KJ, Abrams KR, Muszbek N

**Wed., Nov. 6, 08:30 – 09:30**  
**BREAKOUT SESSION 9**

**W17:** Using Patient Preference Data to Support Clinical Trial Design: Current Practice, Opportunities and Challenges

Marsh K, Morrison D, Oehrlein E, Heidenreich S

**Wed., Nov. 6, 09:45 – 10:45**  
**BREAKOUT SESSION 10**

**W20:** A Quantitative Benefit-Risk Assessment by Applying the Principles of the European Medicines Agency Benefit Risk Assessment Framework and the Publicly Available, Open Source Tool ADDIS: A Hands-On Workshop

Ataheer QS, Postmus D, Hillege HL, Tervonen T

## ISSUE PANEL

**Tue., Nov. 5, 17:00 – 18:00**  
**BREAKOUT SESSION 8**

**IP15:** Reduction of Bias or a Burden? The Use of Individual-Patient Models for Submission to HTA Authorities

Joore M, Caro JJ, Tappenden P, Ramaekers B

## ISPOR FORUM

**Mon., Nov. 4, 12:30 – 13:45**

Value Demonstration and HTA of Next Generation Diagnostic Testing Approaches: Current State and Future Needs for Driving Precision Medicine Expansion

Spinner D, Schroeder B, Ransom J, Siebert U, Faulkner E

## POSTERS

**Mon., Nov. 4**  
**RESEARCH POSTER SESSION 1**

**PNS: NO SPECIFIC DISEASE**

**PNS22:** Using Twitter to Harvest Data from Scientific Conferences: A Proof of Concept of a New Approach to Retrieve Clinical Trial Results

Prawitz T, Kapetanakis V, Ishak KJ

**PNS26:** Using Surrogates for Prediction Overall Survival in Oncology: Considerations for New Treatments and Earlier Stages of Cancer

Sorensen S, Kansal AR, Ishak KJ

**PNS32:** Automatic Abstract Screening Using Machine Learning Techniques: Are We There Yet and How Can We Move Forward?

Rivolo S, Marcell K, Dillon-Murphy D, Sarri G, Benedict A

**PNS202:** Parallel Scientific Advice from NICE and CADTH: What's in it for Manufacturers?

Vania DK, Boss J, Molenkamp L, Hurley PT, Iheanacho I, Bending M, Deshpande S

**PNS250:** CADTH Parallel Scientific Advice Programs with NICE and Health Canada

Boss J, Sood A, Mujoomdar M, Hurley P, Bending M

**PNS346:** Can Meta-Analyses Help in Synthesizing Data Across Health Economic Studies?

Kazmierska P, Akinola T, Abogunrin S

**PSY: SYSTEMIC DISORDERS/CONDITIONS**

**PSY43:** Health State Utilities Associated with Sickle Cell Disease and its Treatment: Literature Review

Deger KA, Gallagher M, Stewart K, Matza LS

**Mon., Nov. 4  
RESEARCH POSTER SESSION 2**

**PCN: CANCER**

**PCN60:** Value of Neoadjuvant IO Therapies with or without Adjuvant Cancer Therapies: A Model Framework

Benedict A, Kovacs V, Gal P, Tichy E

**PCN 150:** Impact of Using Immature Survival Data on NICE Decision-Making

Tai TA, Latimer NR, Benedict A, Kiss Z, Nikolaou A

**PCN 173:** Accounting for Time-Dependent Health State Membership in Budget Impact Analysis - Case Study in Oncology

**AWARD FINALIST**

Litkiewicz M, Ambavane A, Tosh J

**PCN275:** The Global Epidemiology of Peripheral T-Cell Lymphoma: A Systematic Review

Abogunrin S, Panchmatia H, Ovcinnikova O, Dalal M, Ashaye AO

**PCN319:** Contemporary Evidence on Global Economic Burden of Frontline Care for Peripheral T-Cell Lymphoma

Ashaye AO, Abogunrin S, Panchmatia H, Ovcinnikova O, Dalal M

**PCN426:** When Cross-Over Isn't Cross Over. Strategies for Handling Effective Subsequent Therapies in Economic Analysis of Oncology Trials

Chapman R, Kongnakorn T

**PCN453:** Modeling the Impact of Next Generation Sequencing Based Comprehensive Genomic Profiling Panel on Treatment Practices in Advanced or Metastatic Cancer

Quon P, Peng S, Kansal A, Ye W, Spinner D, Feng H, Schroeder B, Faulkner E

**PCN455:** Quality of Life of Patients Living with Metastatic Colorectal Cancer (MCR): Final Results from a European Patient Survey

Benedict A, Rakonczai P, Muszbek N, Maravic Z

**Tue., Nov. 5  
RESEARCH POSTER SESSION 3**

**PDB: DIABETES/ENDOCRINE/METABOLIC DISORDERS**

**PDB106:** Does Mobile Health Live Up to Expectations? Exploring Real-World Experiences in Patients with Diabetes

Booth A, Pan S, Cox A, Merinopoulou E, Oguz M, Halhol S

**PDB112:** Experiences of Patients with Type 2 Diabetes Mellitus Patients in the Kingdom of Saudi Arabia

Strizek AA, Shalhoub H, Matza LS, Jordan J, Anand SB, Boye KS, Alhammad A, Ekhezaimy A, Gelhorn HL

**PIN: INFECTIOUS DISEASES**

**PIN41:** Two-Dose Universal Varicella Vaccination in Brazil: A Model-based Evaluation of Long-Term Health and Cost Impact

Safadi M, Wolfson L, Moreira TNF, Chabrol Haas L, Parelada C, Sutton K, O'Brien E, Gani R, Pawaskar M

**PIN77:** Efficacy Misapplication in Vaccine Modelling

Sutton K, Aponte Ribero V, Roiz J

**PIN86:** Clinical and Economic Outcomes Associated with Varying Coverage of Varicella Vaccination Strategies in Switzerland

Heininger U, Wolfson L, Lienert F, Kyle J, Sutton K, Guggisberg P, Prawitz T, O'Brien E, Gani R, Pawaskar M

**Tue., Nov. 5  
RESEARCH POSTER SESSION 4**

**PCV: CARDIOVASCULAR DISORDERS**

**PCV59:** Hospital Length of Stay among Venous Thromboembolism Patients Treated with Apixaban and Warfarin in England

Carroll R, Lambrelli D, Donaldson R, Ramagopalan S, Alikhan R

**PCV63:** What's the Cost of Hospitalisations Due to Heart Failure with Preserved Ejection Fraction in the United States?

Shamliyan TA, Nambiar S, Martin A

**PCV124:** Reporting and Quality of Patient Preference Studies: A Systematic Literature Review in the Cardiovascular Domain

Duenas A, Yuan Z, Levitan B, Tervonen T

**PCV134:** Mobile Health Technology Perceptions and User Experience among Atrial Fibrillation Patients: A Social Media Listening Study

Halhol S, Pan S, Cox A, Merinopoulou E, Oguz M, Booth A

**PDG: DRUGS & GENERICS**

**PDG6:** A Systematic Literature Review and Network Meta-Analysis (NMA) of Crisaborole 2% Ointment for the Treatment of Mild-to-Moderate Atopic Dermatitis (AD)

Fahrbach K, Tarpey J, Bergrath E, Hughes R, Cha A, Gerber R, Cappelleri JC

**PMU: MULTIPLE DISEASES**

**PMU75:** Consumer Value of Antidiabetic, Antineoplastic, and Respiratory Drugs

**AWARD SEMI-FINALIST**

Ganz ML

**PMU110:** Optimizing Early Access Through Italy's Pharmaceutical Innovation System: Key Success Factors for Attaining Innovative and Conditionally Innovative Status

Sligh S, Kravetz A

**PMU123:** Do Systematic Reviews Systematically Assess Risk of Bias in Real-World Evidence Studies?

Kazmierska P, Gomez Espinosa E, Deshpande S, Iheanacho I

**Wed., Nov. 6  
RESEARCH POSTER SESSION 5**

**PGI: GASTROINTESTINAL DISORDERS**

**PGI9:** Cost-Effectiveness of Tofacitinib Compared with Infliximab, Adalimumab, Golimumab and Vedolizumab for the Treatment of Moderate to Severe Ulcerative Colitis in Germany

Quon P, Sardesai A, Milev S, DiBonaventura M, Cappelleri JC, Kissar A, Modesto I, Dietz L, Dignass A, Bargo D

**PIH: INDIVIDUAL'S HEALTH**

**PIH54:** Health Related Quality of Life of Pre-Adolescent Deaf Children with Cochlear Implants: A Conceptual Disease Model

Cooper O

**PND: NEUROLOGICAL DISORDERS**

**PND93:** What Good are Digital Technologies in Alzheimer's Disease Research? - A Systematic Literature Review

Vinals L, Akinola T, Sarri G

**PRO: RARE & ORPHAN DISEASES**

**PRO6:** Translation and Linguistic Validation of the Hemophilia Quality of Life (Haemo-QoL-A) Questionnaire for Use with Hemophilia Patients

Parks-Vernizzi E, Benjamin A, Herzberg T, Rentz A, Light E

**PRO69:** Epidemiological Model to Support Orphan Designation Decisions: A DICE Simulation Study

Mohseninejad L, Pelligra C, Caro JJ

**PRO89:** Too Ultra-Rare for Care? Orphan Drug Availability for Respiratory Diseases: A Systematic Review

**AWARD FINALIST**

Matthews H, Lovelace M, Freitag A, Iheanacho I

**PRO109:** A Comparative Review of NICE and SMC Decision-Making for Ultra-Orphan Medicines

Gibbs K, Schmetz A, Emich H, Gardner K

WITHDRAWN